


ELI LILLY AND COMPANY

ISIN: US5324571083 WKN: 532457108 Asset Class: Stock

Company 2024/05/02 22:00:02



Price
755.91
USD

Difference ▼ -2.68% (-20.84)



Contact Details

ELI LILLY & CO. Tel: +1-317-276-2000
 -- Fax: +
 Lilly Corporate Center Web: <http://www.lilly.com>
 46285 Indianapolis E-mail: communications_corporate@lilly.com

Company Profile

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	25,727,000,000		18,034,500,000		18,452,400,000	
Common stock capital		593,600,000		594,100,000		596,300,000
Fixed assets	38,279,300,000		31,455,300,000		30,353,600,000	
Equity capital of a company		10,863,700,000		10,775,400,000		9,154,800,000
Cash and cash equivalents	2,818,600,000		2,067,000,000		3,818,500,000	
Accrued liabilities		1,438,800,000		1,305,100,000		1,954,100,000
Other assets	-		-		-	
Current liabilities		27,293,200,000		17,138,200,000		15,052,700,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		25,849,400,000		21,576,200,000		24,598,500,000
Different income		-		-		-
Other liabilities		6,089,800,000		5,446,300,000		5,564,300,000
Total assets	64,006,300,000	64,006,300,000	49,489,800,000	49,489,800,000	48,806,000,000	48,806,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	43,000	39,000	35,000
Equity ratio	17.12%	22.03%	19.12%
Debt-equity ratio	484.24%	353.99%	423.09%

Others

	2023	2022	2021
Tax Expense Rate	20.05%	8.25%	9.32%

ELI LILLY AND COMPANY

ISIN: US5324571083 WKN: 532457108 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	34,124,100,000	28,541,400,000	28,318,400,000
Net income	5,240,400,000	6,244,800,000	5,581,700,000
EBIT	6,438,405,440	6,633,707,520	6,066,178,240
Operating income before taxes	6,554,600,000	6,806,400,000	6,155,500,000
Cash Flow	4,240,100,000	7,084,400,000	7,260,700,000
Net interest income	-312,300,000	-268,800,000	-314,400,000
Research and development expenses	9,313,400,000	7,190,800,000	7,025,900,000
Income taxes	1,314,200,000	561,600,000	573,800,000
Result from investments in subsidiaries, associates and other	0	-	-
Revenues per employee	744,064	686,165	758,609

Board of Directors

Members of Management Board

Katherine Baicker	Member of Board of Directors
Marschall Runge	Member of Board of Directors
Mary Lynne Hedley	Member of Board of Directors
William Kaelin	Member of Board of Directors
Gabrielle Greene-Sulzberger	Member of Board of Directors
Jamere Jackson	Member of Board of Directors
Jon Fyrwald	Member of Board of Directors
Juan Luciano	Member of Board of Directors
Karen Walker	Member of Board of Directors
Kimberly Johnson	Member of Board of Directors
Ralph Alvarez	Member of Board of Directors
David Ricks	Chairman of Managing Board
Alonzo Weems	Member of Executive Committee
Anat Ashkenazi	Member of Executive Committee
Anat Hakim	Member of Executive Committee
Anne E. White	Member of Executive Committee
Daniel M. Skovronsky	Member of Executive Committee
Diogo Rau	Member of Executive Committee
Edgardo Hernandez	Member of Executive Committee
Eric Dozier	Member of Executive Committee
Ilya Yuffa	Member of Executive Committee
Jacob Van Naarden	Member of Executive Committee
Johna L. Norton	Member of Executive Committee
Patrik Jonsson	Member of Executive Committee